{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T20:41:27Z","timestamp":1782333687586,"version":"3.54.5"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["GA4-177773"],"award-info":[{"award-number":["GA4-177773"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"crossref","award":["202309PPE-512214"],"award-info":[{"award-number":["202309PPE-512214"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Persistent symptoms following SARS-CoV-2 infection are the hallmark of post-COVID condition (PCC), also referred to as long COVID. However, the underlying molecular mechanisms remain poorly understood. In this study, we employed data-independent acquisition mass spectrometry (DIA-MS)-based plasma proteomics to identify molecular alterations associated with PCC. DIA-MS proteomic analysis revealed a clear distinction between the plasma proteome of uninfected individuals and those previously infected with SARS-CoV-2, irrespective of PCC status. PCC samples demonstrated downregulation of the antioxidant protein peroxiredoxin 6 (PRDX6) and upregulation of oxidative stress\u2013associated proteins, particularly vanin-1 (VNN1) and paraoxonase-3 (PON3). Additionally, individuals with PCC exhibited significantly elevated levels of six proteins\u2014PCSK9, CST3, C1Q, CPB2, KNG1, and GAPDH\u2014associated with glycolysis, complement and coagulation cascades, and inflammatory pathways. Validation by ELISA does not necessarily reflect the proteomics data suggesting the requirement for alternate methods of validation. Nonetheless, oxidative stress, as measured by 8-hydroxy-2\u2032-deoxyguanosine (8-OHdG), further showed that PCC samples had significantly higher levels of DNA damage, compared with convalescent individuals. Antioxidant markers, including reduced and oxidized glutathione (GSH and GSSG), were significantly lower in PCC samples than in uninfected controls. Collectively, these findings indicate that plasma proteomic alterations persist for at least 3\u00a0months following SARS-CoV-2 infection, with additional disruptions in oxidative stress and inflammatory pathways characterizing individuals with PCC.<\/jats:p>","DOI":"10.1038\/s41598-026-46180-y","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T10:47:29Z","timestamp":1776422849000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Distinct plasma proteome signature at 3\u00a0months post-COVID-19 infection irrespective of post-COVID condition"],"prefix":"10.1038","volume":"16","author":[{"given":"Mohammad Mobarak H.","family":"Chowdhury","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akouavi Julite Irmine","family":"Quenum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rioux-Perreault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Lucier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subburaj","family":"Ilangumaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Pich\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugues","family":"Allard-Chamard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheela","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"issue":"8","key":"46180_CR1","first-page":"4572","volume":"24","author":"P Pavone","year":"2020","unstructured":"Pavone, P., Ceccarelli, M., Taibi, R., La Rocca, G. & Nunnari, G. Outbreak of COVID-19 infection in children: Fear and serenity.. Eur. Rev. Med. Pharmacol. Sci. 24(8), 4572\u20134575 (2020).","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"issue":"10","key":"46180_CR2","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2020.35.e112","volume":"35","author":"Korean Society of Infectious D","year":"2020","unstructured":"Korean Society of Infectious D et al. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J. Korean Med. Sci. 35(10), e112 (2020).","journal-title":"J. Korean Med. Sci."},{"key":"46180_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2815","volume":"370","author":"E Mahase","year":"2020","unstructured":"Mahase, E. COVID-19: What do we know about \u201clong COVID\u201d?. BMJ 370, m2815 (2020).","journal-title":"BMJ"},{"issue":"6","key":"46180_CR4","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1001\/jama.2020.12603","volume":"324","author":"A Carfi","year":"2020","unstructured":"Carfi, A., Bernabei, R. & Landi, F. Gemelli against C-P-ACSG: Persistent symptoms in patients after acute COVID-19. JAMA 324(6), 603\u2013605 (2020).","journal-title":"JAMA"},{"issue":"3","key":"46180_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-048391","volume":"11","author":"A Dennis","year":"2021","unstructured":"Dennis, A. et al. Multiorgan impairment in low-risk individuals with post-COVID-19 syndrome: A prospective, community-based study. BMJ Open 11(3), e048391 (2021).","journal-title":"BMJ Open"},{"issue":"1","key":"46180_CR6","doi-asserted-by":"publisher","first-page":"6571","DOI":"10.1038\/s41467-021-26513-3","volume":"12","author":"Y Xie","year":"2021","unstructured":"Xie, Y., Bowe, B. & Al-Aly, Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. Nat. Commun. 12(1), 6571 (2021).","journal-title":"Nat. Commun."},{"issue":"3","key":"46180_CR7","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","volume":"21","author":"HE Davis","year":"2023","unstructured":"Davis, H. E., McCorkell, L., Vogel, J. M. & Topol, E. J. Long COVID: Major findings, mechanisms and recommendations. Nat. Rev. Microbiol. 21(3), 133\u2013146 (2023).","journal-title":"Nat. Rev. Microbiol."},{"issue":"10350","key":"46180_CR8","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S0140-6736(22)01214-4","volume":"400","author":"AV Ballering","year":"2022","unstructured":"Ballering, A. V., van Zon, S. K. R., Olde Hartman, T. C., Rosmalen, J. G. M., Lifelines Corona Research I. Persistence of somatic symptoms after COVID-19 in the Netherlands: An observational cohort study. Lancet 400(10350), 452\u2013461 (2022).","journal-title":"Lancet"},{"issue":"12","key":"46180_CR9","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1038\/s41591-020-01177-6","volume":"26","author":"Meeting the challenge of long COVID","year":"2020","unstructured":"Meeting the challenge of long COVID. Nat. Med. 26(12), 1803 (2020).","journal-title":"Nat. Med."},{"key":"46180_CR10","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1111\/apa.15870","volume":"110","author":"D Buonsenso","year":"2021","unstructured":"Buonsenso, D. et al. Preliminary evidence on long COVID in children. Acta Paediatr. 110, 2208 (2021).","journal-title":"Acta Paediatr."},{"issue":"16","key":"46180_CR11","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1001\/jama.2022.18931","volume":"328","author":"S Wulf Hanson","year":"2022","unstructured":"Global Burden of Disease Long CC et al. Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA 328(16), 1604\u20131615 (2022).","journal-title":"JAMA"},{"issue":"8","key":"46180_CR12","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1001\/jama.2024.24184","volume":"333","author":"LN Geng","year":"2025","unstructured":"Geng, L. N. et al. 2024 update of the RECOVER-adult long COVID research index. JAMA 333(8), 694\u2013700 (2025).","journal-title":"JAMA"},{"key":"46180_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-072529","volume":"380","author":"B Mizrahi","year":"2023","unstructured":"Mizrahi, B. et al. Long COVID outcomes at one year after mild SARS-CoV-2 infection: Nationwide cohort study. BMJ 380, e072529 (2023).","journal-title":"BMJ"},{"key":"46180_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01283-z","author":"A Nalbandian","year":"2021","unstructured":"Nalbandian, A. et al. Post-acute COVID-19 syndrome. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-021-01283-z (2021).","journal-title":"Nat. Med."},{"issue":"10223","key":"46180_CR15","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","volume":"395","author":"C Huang","year":"2020","unstructured":"Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 395(10223), 497\u2013506 (2020).","journal-title":"Lancet"},{"issue":"1","key":"46180_CR16","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36142","volume":"4","author":"M Bellan","year":"2021","unstructured":"Bellan, M. et al. Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw. Open 4(1), e2036142 (2021).","journal-title":"JAMA Netw. Open"},{"key":"46180_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s00408-021-00423-z","volume":"199","author":"DL Sykes","year":"2021","unstructured":"Sykes, D. L. et al. Post-COVID-19 symptom burden: What is Long-COVID and how should we manage it?. Lung 199, 113\u2013119 (2021).","journal-title":"Lung"},{"key":"46180_CR18","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1038\/s41591-021-01292-y","volume":"27","author":"CH Sudre","year":"2021","unstructured":"Sudre, C. H. et al. Attributes and predictors of long COVID. Nat. Med. 27, 626\u2013631 (2021).","journal-title":"Nat. Med."},{"key":"46180_CR19","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13746","author":"M Kamal","year":"2020","unstructured":"Kamal, M., Abo Omirah, M., Hussein, A. & Saeed, H. Assessment and characterisation of post-COVID-19 manifestations. Int. J. Clin. Pract. https:\/\/doi.org\/10.1111\/ijcp.13746 (2020).","journal-title":"Int. J. Clin. Pract."},{"issue":"4","key":"46180_CR20","doi-asserted-by":"publisher","first-page":"e102","DOI":"10.1016\/S1473-3099(21)00703-9","volume":"22","author":"JB Soriano","year":"2022","unstructured":"Soriano, J. B. et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect. Dis. 22(4), e102\u2013e107 (2022).","journal-title":"Lancet Infect. Dis."},{"issue":"2","key":"46180_CR21","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/s41590-021-01104-y","volume":"23","author":"S Mehandru","year":"2022","unstructured":"Mehandru, S. & Merad, M. Pathological sequelae of long-haul COVID. Nat. Immunol. 23(2), 194\u2013202 (2022).","journal-title":"Nat. Immunol."},{"key":"46180_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24087445","author":"A Stufano","year":"2023","unstructured":"Stufano, A. et al. Oxidative damage and post-COVID syndrome: A cross-sectional study in a cohort of Italian workers. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms24087445 (2023).","journal-title":"Int. J. Mol. Sci."},{"key":"46180_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103310","volume":"76","author":"LE Vlaming-van Eijk","year":"2024","unstructured":"Vlaming-van Eijk, L. E. et al. Systemic oxidative stress associates with the development of post-COVID-19 syndrome in non-hospitalized individuals. Redox Biol. 76, 103310 (2024).","journal-title":"Redox Biol."},{"key":"46180_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/antiox10020257","author":"J Pincemail","year":"2021","unstructured":"Pincemail, J. et al. Oxidative stress status in COVID-19 patients hospitalized in intensive care unit for severe pneumonia. A pilot study. Antioxidants https:\/\/doi.org\/10.3390\/antiox10020257 (2021).","journal-title":"Antioxidants"},{"key":"46180_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.freeradbiomed.2023.06.026","volume":"207","author":"FF Neves","year":"2023","unstructured":"Neves, F. F. et al. Do the oxidative stress biomarkers predict COVID-19 outcome? An in-hospital cohort study. Free Radic. Biol. Med. 207, 194\u2013199 (2023).","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"46180_CR26","doi-asserted-by":"publisher","DOI":"10.1080\/13510002.2025.2471738","volume":"30","author":"PM Valente Coronel","year":"2025","unstructured":"Valente Coronel, P. M. et al. Involvement of oxidative stress in post-acute sequelae of COVID-19: Clinical implications. Redox Rep. 30(1), 2471738 (2025).","journal-title":"Redox Rep."},{"issue":"5","key":"46180_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245031","volume":"16","author":"K Tremblay","year":"2021","unstructured":"Tremblay, K. et al. The Biobanque quebecoise de la COVID-19 (BQC19)-A cohort to prospectively study the clinical and biological determinants of COVID-19 clinical trajectories. PLoS ONE 16(5), e0245031 (2021).","journal-title":"PLoS ONE"},{"key":"46180_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1223936","volume":"14","author":"MA Limoges","year":"2023","unstructured":"Limoges, M. A. et al. SARS-CoV-2 spike antigen-specific B cell and antibody responses in pre-vaccination period COVID-19 convalescent males and females with or without post-COVID condition. Front. Immunol. 14, 1223936 (2023).","journal-title":"Front. Immunol."},{"key":"46180_CR29","unstructured":"WHO. A clinical case definition of post COVID-19 condition by a Delphi consensus. October 6, 2021. https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (2021)."},{"key":"46180_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2024.1416639","volume":"15","author":"MMH Chowdhury","year":"2024","unstructured":"Chowdhury, M. M. H. et al. Impact of a tailored exercise regimen on physical capacity and plasma proteome profile in post-COVID-19 condition. Front. Physiol. 15, 1416639 (2024).","journal-title":"Front. Physiol."},{"issue":"1","key":"46180_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","volume":"17","author":"V Demichev","year":"2020","unstructured":"Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: Neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods 17(1), 41\u201344 (2020).","journal-title":"Nat. Methods"},{"key":"46180_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1034159","volume":"13","author":"P Chattopadhyay","year":"2022","unstructured":"Chattopadhyay, P. et al. Single-cell multiomics revealed the dynamics of antigen presentation, immune response and T cell activation in the COVID-19 positive and recovered individuals. Front. Immunol. 13, 1034159 (2022).","journal-title":"Front. Immunol."},{"key":"46180_CR33","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3764515","volume":"2020","author":"D Chen","year":"2020","unstructured":"Chen, D. et al. Serum cystatin C and coronavirus disease 2019: A potential inflammatory biomarker in predicting critical illness and mortality for adult patients. Mediators Inflamm. 2020, 3764515 (2020).","journal-title":"Mediators Inflamm."},{"key":"46180_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/v15071511","author":"P Mester","year":"2023","unstructured":"Mester, P. et al. Plasma proprotein convertase subtilisin\/kexin type 9 (PCSK9) as a possible biomarker for severe COVID-19. Viruses https:\/\/doi.org\/10.3390\/v15071511 (2023).","journal-title":"Viruses"},{"issue":"15","key":"46180_CR35","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.7150\/ijms.102879","volume":"21","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. Oxidative stress indexes as biomarkers of the severity in COVID-19 patients. Int. J. Med. Sci. 21(15), 3034\u20133045 (2024).","journal-title":"Int. J. Med. Sci."},{"issue":"4","key":"46180_CR36","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/mutage\/gead021","volume":"38","author":"S Kankaya","year":"2023","unstructured":"Kankaya, S. et al. Glutathione-related antioxidant defence, DNA damage, and DNA repair in patients suffering from post-COVID conditions. Mutagenesis 38(4), 216\u2013226 (2023).","journal-title":"Mutagenesis"},{"issue":"9","key":"46180_CR37","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.7326\/M24-0737","volume":"177","author":"KM Erlandson","year":"2024","unstructured":"Erlandson, K. M. et al. Differentiation of prior SARS-CoV-2 infection and postacute sequelae by standard clinical laboratory measurements in the RECOVER Cohort. Ann. Intern. Med. 177(9), 1209\u20131221 (2024).","journal-title":"Ann. Intern. Med."},{"issue":"3","key":"46180_CR38","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1089\/ars.2010.3412","volume":"15","author":"AB Fisher","year":"2011","unstructured":"Fisher, A. B. Peroxiredoxin 6: A bifunctional enzyme with glutathione peroxidase and phospholipase A(2) activities. Antioxid. Redox Signal. 15(3), 831\u2013844 (2011).","journal-title":"Antioxid. Redox Signal."},{"issue":"3","key":"46180_CR39","doi-asserted-by":"publisher","first-page":"590","DOI":"10.3390\/antiox11030590","volume":"11","author":"CJ Mohammed","year":"2022","unstructured":"Mohammed, C. J. et al. A PON for all seasons: Comparing paraoxonase enzyme substrates, activity and action including the role of PON3 in health and disease. Antioxidants (Basel) 11(3), 590 (2022).","journal-title":"Antioxidants (Basel)"},{"issue":"17","key":"46180_CR40","doi-asserted-by":"publisher","first-page":"4569","DOI":"10.1182\/blood-2010-09-304931","volume":"117","author":"B Zhang","year":"2011","unstructured":"Zhang, B. et al. The role of vanin-1 and oxidative stress-related pathways in distinguishing acute and chronic pediatric ITP. Blood 117(17), 4569\u20134579 (2011).","journal-title":"Blood"},{"issue":"12","key":"46180_CR41","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3390\/biom9120817","volume":"9","author":"K Priyanka","year":"2019","unstructured":"Priyanka, K., Singh, S. & Gill, K. Paraoxonase 3: Structure and its role in pathophysiology of coronary artery disease. Biomolecules 9(12), 817 (2019).","journal-title":"Biomolecules"},{"key":"46180_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2023.176220","volume":"962","author":"H Yu","year":"2024","unstructured":"Yu, H. et al. Vanin1 (VNN1) in chronic diseases: Future directions for targeted therapy. Eur. J. Pharmacol. 962, 176220 (2024).","journal-title":"Eur. J. Pharmacol."},{"issue":"6","key":"46180_CR43","doi-asserted-by":"publisher","first-page":"864","DOI":"10.3390\/antiox10060864","volume":"10","author":"T Tomin","year":"2021","unstructured":"Tomin, T. et al. Blood plasma quality control by plasma glutathione status. Antioxidants (Basel) 10(6), 864 (2021).","journal-title":"Antioxidants (Basel)"},{"issue":"13","key":"46180_CR44","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202500677RR","volume":"39","author":"D Giustarini","year":"2025","unstructured":"Giustarini, D., Colella, S., Dalle-Donne, I. & Rossi, R. Homocysteine: Canary in the coal mine or hidden threat? A biochemical study on the role of plasma thiols. FASEB J. 39(13), e70772 (2025).","journal-title":"FASEB J."},{"key":"46180_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105029","volume":"101","author":"X Gu","year":"2024","unstructured":"Gu, X., Wong, C. C. L. & Cao, B. Authors\u2019 reply to letter regarding \u201cProbing long COVID through a proteomic lens: A comprehensive two-year longitudinal cohort study of hospitalised survivor\u201d. EBioMedicine 101, 105029 (2024).","journal-title":"EBioMedicine"},{"key":"46180_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104851","volume":"98","author":"X Gu","year":"2023","unstructured":"Gu, X. et al. Probing long COVID through a proteomic lens: A comprehensive two-year longitudinal cohort study of hospitalised survivors. EBioMedicine 98, 104851 (2023).","journal-title":"EBioMedicine"},{"key":"46180_CR47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2024.105023","volume":"101","author":"C Yang","year":"2024","unstructured":"Yang, C., Shannon, C. P. & Tebbutt, S. J. Unravelling long COVID: Insights from proteomics and considerations for comprehensive understanding. EBioMedicine 101, 105023 (2024).","journal-title":"EBioMedicine"},{"issue":"11","key":"46180_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101254","volume":"4","author":"K Wang","year":"2023","unstructured":"Wang, K. et al. Sequential multi-omics analysis identifies clinical phenotypes and predictive biomarkers for Long COVID. Cell Rep. Med. 4(11), 101254 (2023).","journal-title":"Cell Rep. Med."},{"issue":"4","key":"46180_CR49","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/s41590-025-02110-0","volume":"26","author":"G Canderan","year":"2025","unstructured":"Canderan, G. et al. Distinct type 1 immune networks underlie the severity of restrictive lung disease after COVID-19. Nat. Immunol. 26(4), 595\u2013606 (2025).","journal-title":"Nat. Immunol."},{"issue":"6680","key":"46180_CR50","doi-asserted-by":"publisher","first-page":"eadg7942","DOI":"10.1126\/science.adg7942","volume":"383","author":"C Cervia-Hasler","year":"2024","unstructured":"Cervia-Hasler, C. et al. Persistent complement dysregulation with signs of thromboinflammation in active long Covid. Science 383(6680), eadg7942 (2024).","journal-title":"Science"},{"key":"46180_CR51","doi-asserted-by":"publisher","first-page":"1575135","DOI":"10.3389\/fimmu.2025.1575135","volume":"16","author":"D Wolday","year":"2025","unstructured":"Wolday, D. et al. Distinct proteomic signatures in Ethiopians predict acute and long-term sequelae of COVID-19. Front. Immunol. 16, 1575135 (2025).","journal-title":"Front. Immunol."},{"issue":"5","key":"46180_CR52","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/s41590-025-02135-5","volume":"26","author":"Y Gao","year":"2025","unstructured":"Gao, Y. et al. Identification of soluble biomarkers that associate with distinct manifestations of long COVID. Nat. Immunol. 26(5), 692\u2013705 (2025).","journal-title":"Nat. Immunol."},{"key":"46180_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.730710","volume":"12","author":"M Villar","year":"2021","unstructured":"Villar, M. et al. Characterization by quantitative serum proteomics of immune-related prognostic biomarkers for COVID-19 symptomatology. Front. Immunol. 12, 730710 (2021).","journal-title":"Front. Immunol."},{"issue":"6","key":"46180_CR54","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.3390\/jcm11061494","volume":"11","author":"K Claesen","year":"2022","unstructured":"Claesen, K. et al. Activation of the carboxypeptidase U (CPU, TAFIa, CPB2) system in patients with SARS-CoV-2 infection could contribute to COVID-19 hypofibrinolytic state and disease severity prognosis. J. Clin. Med. 11(6), 1494 (2022).","journal-title":"J. Clin. Med."},{"issue":"15","key":"46180_CR55","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037802","volume":"103","author":"N Altin","year":"2024","unstructured":"Altin, N. et al. A challenging issue in COVID-19 infection: The relationship between PA1-1 and TAFI levels in patients with coagulation disorder: A retrospective and observational study. Medicine (Baltimore) 103(15), e37802 (2024).","journal-title":"Medicine (Baltimore)"},{"issue":"11","key":"46180_CR56","doi-asserted-by":"publisher","first-page":"4727","DOI":"10.1074\/jbc.M116.759084","volume":"292","author":"H Nakajima","year":"2017","unstructured":"Nakajima, H. et al. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) aggregation causes mitochondrial dysfunction during oxidative stress-induced cell death. J. Biol. Chem. 292(11), 4727\u20134742 (2017).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"46180_CR57","doi-asserted-by":"publisher","first-page":"2610","DOI":"10.1038\/s41467-023-37567-w","volume":"14","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. Neutrophil metabolomics in severe COVID-19 reveal GAPDH as a suppressor of neutrophil extracellular trap formation. Nat. Commun. 14(1), 2610 (2023).","journal-title":"Nat. Commun."},{"issue":"1","key":"46180_CR58","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1159\/000535634","volume":"16","author":"R Dilawari","year":"2024","unstructured":"Dilawari, R. et al. Glyceraldehyde-3-phosphate dehydrogenase binds with spike protein and inhibits the entry of SARS-CoV-2 into host cells. J. Innate Immun. 16(1), 133\u2013142 (2024).","journal-title":"J. Innate Immun."},{"key":"46180_CR59","doi-asserted-by":"publisher","DOI":"10.1101\/2024.05.04.592477","author":"V Shankar","year":"2024","unstructured":"Shankar, V. et al. Oxidative stress is a shared characteristic of ME\/CFS and long COVID. bioRxiv https:\/\/doi.org\/10.1101\/2024.05.04.592477 (2024).","journal-title":"bioRxiv"},{"issue":"10","key":"46180_CR60","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.3390\/metabo13101032","volume":"13","author":"S Mrakic-Sposta","year":"2023","unstructured":"Mrakic-Sposta, S. et al. Hyperbaric oxygen therapy counters oxidative stress\/inflammation-driven symptoms in long COVID-19 patients: Preliminary outcomes. Metabolites 13(10), 1032 (2023).","journal-title":"Metabolites"},{"issue":"9","key":"46180_CR61","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1007\/s00726-023-03305-1","volume":"55","author":"M Mikuteit","year":"2023","unstructured":"Mikuteit, M. et al. Amino acids, post-translational modifications, nitric oxide, and oxidative stress in serum and urine of long COVID and ex COVID human subjects. Amino Acids 55(9), 1173\u20131188 (2023).","journal-title":"Amino Acids"},{"issue":"2","key":"46180_CR62","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1038\/s41380-022-01836-9","volume":"28","author":"HK Al-Hakeim","year":"2023","unstructured":"Al-Hakeim, H. K., Al-Rubaye, H. T., Al-Hadrawi, D. S., Almulla, A. F. & Maes, M. Long-COVID post-viral chronic fatigue and affective symptoms are associated with oxidative damage, lowered antioxidant defenses and inflammation: A proof of concept and mechanism study. Mol. Psychiatry 28(2), 564\u2013578 (2023).","journal-title":"Mol. Psychiatry"},{"issue":"2","key":"46180_CR63","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1515\/nipt-2022-0006","volume":"2","author":"MG Saleh","year":"2023","unstructured":"Saleh, M. G. et al. Ongoing oxidative stress in individuals with post-acute sequelae of COVID-19. NeuroImmune Pharm. Ther. 2(2), 89\u201394 (2023).","journal-title":"NeuroImmune Pharm. Ther."},{"key":"46180_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2025.105792","volume":"117","author":"O Robineau","year":"2025","unstructured":"Robineau, O. et al. Symptoms and pathophysiology of post-acute sequelae following COVID-19 (PASC): A cohort study. EBioMedicine 117, 105792 (2025).","journal-title":"EBioMedicine"},{"issue":"8","key":"46180_CR65","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1038\/s41591-022-01909-w","volume":"28","author":"A Subramanian","year":"2022","unstructured":"Subramanian, A. et al. Symptoms and risk factors for long COVID in non-hospitalized adults. Nat. Med. 28(8), 1706\u20131714 (2022).","journal-title":"Nat. Med."},{"issue":"9","key":"46180_CR66","doi-asserted-by":"publisher","first-page":"2707","DOI":"10.1007\/s11136-023-03406-0","volume":"32","author":"P Tanguay","year":"2023","unstructured":"Tanguay, P. et al. Trajectories of health-related quality of life and their predictors in adult COVID-19 survivors: A longitudinal analysis of the Biobanque Quebecoise de la COVID-19 (BQC-19). Qual. Life Res. 32(9), 2707\u20132717 (2023).","journal-title":"Qual. Life Res."},{"issue":"9","key":"46180_CR67","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S2213-2600(22)00126-6","volume":"10","author":"L Huang","year":"2022","unstructured":"Huang, L. et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: A longitudinal cohort study. Lancet Respir. Med. 10(9), 863\u2013876 (2022).","journal-title":"Lancet Respir. Med."},{"issue":"2","key":"46180_CR68","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41590-023-01724-6","volume":"25","author":"K Yin","year":"2024","unstructured":"Yin, K. et al. Long COVID manifests with T cell dysregulation, inflammation and an uncoordinated adaptive immune response to SARS-CoV-2. Nat. Immunol. 25(2), 218\u2013225 (2024).","journal-title":"Nat. Immunol."},{"issue":"4","key":"46180_CR69","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41590-024-01778-0","volume":"25","author":"F Liew","year":"2024","unstructured":"Liew, F. et al. Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nat. Immunol. 25(4), 607\u2013621 (2024).","journal-title":"Nat. Immunol."},{"issue":"1","key":"46180_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2023-002137","volume":"11","author":"H Takaoka","year":"2024","unstructured":"Takaoka, H. et al. Long COVID among the first three waves of COVID-19 in Japan: A multicentre cohort study. BMJ Open Respir. Res. 11(1), e002137 (2024).","journal-title":"BMJ Open Respir. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46180-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46180-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46180-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:03:40Z","timestamp":1781222620000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46180-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46180"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46180-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"assertion":[{"value":"25 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HAC received research funds from Janssen, Eli Lilly, Fresenius Kabi and Pfizer, but nothing related to the current manuscript. He also participated in medical education of Pfizer which was conducing trial on PCC, but nothing directly related to the current manuscript or that could impact our interpretation of data. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The human studies were approved by the Institutional human ethics committee, CIUSSS de l\u2019Estrie\u2014CHUS, Universit\u00e9 de Sherbrooke (Approval Number 2022-4415).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"Informed consent was obtained from all subjects involved in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"18201"}}